An observational study in Infective Endocarditis, Response, Acute Phase and Treatment, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.
Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Observational
The hypothesis underlying this work is the identification of different sub phenotypes of patients with infective endocarditis through the study of the host's response to infection.
Furthemore, metagenomic sequencing may be a helpful supplement to IE diagnostic, especially when conventional tests fail to yield a diagnosis.
Infective endocarditis is a life-threatening infection of heart valves and adjacent structures characterized by vegetations on valves and other endocardial surfaces, with tissue destruction and risk of embolization.
The clinical variability, including the heterogeneous response to infection and the different antibiotic treatments make the identification of the underlying pathogens of infective endocarditis (IE) is critical for precision therapy. Virulence factors mediate tissue adherence, host infiltration, immune resistance/evasion, and dynamic stress responses and confer enhanced pathogen survival, proliferation, and host invasion in animal models of infective endocarditis.
To identify the microorganism and simultaneously considered the response of the host to the infection could improve the management of the infective endocarditis.
173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.
This study's enrollment of 32 is below the median of 225 across 82 observational studies indexed under Endocarditis.
Browse Endocarditis studies →Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with an active infective endocarditis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To characterize a cohort of patients diagnosed with infective endocarditis
Clinical, microbiological and echocardiographic description of patients with infective endocarditis.
Time frame: 2 year
Identification of the underlying pathogens of infective endocarditis (IE)
We will employ next-generation sequencing for pathogens and antimicrobial resistance detection in IE patients.
Time frame: 2 year
Host response classification for infective endocarditis (IE)
Differential baseline expression of some genes may indicate resilience to infection.
Time frame: 2 year
Host response predictors of sepsis outcomes
We will develop and use advanced bioinformatic, metabolomic, proteomic and mRNA sequencing technologies to identify specific changes, or biomarkers, in patient blood samples that predict outcome in sepsis.
Time frame: 2 year
Plan to share: Yes — All datasets underlying the study are available upon request to the study principal investigator. All of the individual participant data collected during the trial, informed consent forms, study protocol, statistical analysis plan and raw data, are available under reasonable request, and after deindentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Starting 3 month after publication
Access criteria: Principal investigator will review requests of data to be provided.
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación Biosanitaria del Principado de Asturias